Skip to content

Addressing Personalized Needs in Clostridioides Difficile Infection

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: Study Phase 1

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04725123
Acronym
BEYOND
Enrollment
153
Registered
2021-01-26
Start date
2021-01-26
Completion date
2022-03-27
Last updated
2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clostridioides Difficile Infection

Keywords

Clostridioides difficile, Microbiome, Prediction, Unfavorable outcome

Brief summary

BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at great likelihood for CDI with unfavorable outcome are early detected

Detailed description

In a previous project, following GWAS analysis of the DNA and measurement of serum biomarkers coming from 134 patients a prediction score named SPECIFY was developed. The SPECIFY score comprises four elements: low hemoglobin, increased urea, increased IL-8 and carriage of G alleles of rs2091172. The score has 80% positive predictive value and 95.8% specificity for the early detection of unfavorable outcome but the sensitivity is low. Unfavorable outcome is defined as any of: presentation or progression into severe CDI, relapse; and death. Stool samples of day 1 before start of therapy of the patients are stored refrigerated. Microbiome analysis will be done aiming to the integration of the Shannon diversity index to the already developed score in order to improve sensitivity.

Interventions

DIAGNOSTIC_TESTMicrobiome analysis

Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads

Sponsors

Hellenic Institute for the Study of Sepsis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than or equal to 18 years * Both genders * Diarrhea defined as at least 3 episodes of unformed stools in the last 24hours according to the Bristol stool chart * Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.

Exclusion criteria

• No

Design outcomes

Primary

MeasureTime frameDescription
Prediction of unfavorable outcome40 daysSensitivity of the BEYOND score to predict unfavorable outcome of patients with infection by Clostridioides difficile

Secondary

MeasureTime frameDescription
Diagnostic PCR reaction in stool40 daysDevelopment of one RT-PCR reaction informing of the predominance of bacterial generum causing low microbiome diversity associated with the unfavorable outcome of CDI.

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026